I currently have a healthy accumulation of shares in the company and completely believe in everything they are currently working on (as a medical student). But I am wondering what we think the likely hood of a dilution vote passing might be, and what exactly that will mean for those of us (including myself) that bought the stock a little later on at $1.50/share or higher. Any input is appreciated.
That's what I'd like to be able to do ideally, but I don't have enough funds to spread myself that thin. Thank you all for your advice. I have a strong feeling that by late 2014-early 2015 we will see federal funding for a large quantity of stem cell research companies (especially the less controversial ones).
wahnton is correct mzecchini89. absolutely on spot.(i remember my 1st i.d. card at osu in 1977 read $545 for tuition paid....dont know if that would even cover 15hrs credit hrs of books now a days.lol.but maybe athx gains by july will help you,good luck in school)JMHO
Frankly I don't think it's going to mean much either way in the short term as the extra 5 or 10% dilution or whatever it may be isn't a big negative. What would be a big negative would be one of their clinical trials going south or a partnership deal on bad terms. If the company becomes successful and establishes a pattern of positive earnings, then it may come into play down the line, but we have a long way to go before that happens- if it happens.
Bottom line: I think it's likely and I think it doesn't matter in the big picture.
I understand this is a stock that will most likely begin to show maturity in about 1 year. But I was under the impression that the dilution ratio was going to be closer to that of 40-50%. But then again I could have misread the articles, but from what it highlighted was about a $2.07 dilution to about $1.